Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease

Nephron - Clinical Practice

Volumn 123, Issue 1-2, 2013, Pages 61-66

  Spatz, Christin ^a   Roe, Kevin ^a   Lehman, Erik ^b   Verma, Navin ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Fibroblast growth factor 23; Hyperphosphatemia; Non calcium based phosphate binder; Sevelamer carbonate

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHORUS; SEVELAMER CARBONATE; VITAMIN D;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADULT; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE TITRATION; PROTEIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGED; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84882305781     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000351811     Document Type: Article

References (21)

1. Giachelli CM: The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897.
2. Neves KR, et al: Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004; 66: 2237-2244.
3. Tonelli M, et al: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
4. Kestenbaum B, et al: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
5. Schiavi SC: Fibroblast growth factor 23: the making of a hormone. Kidney Int 2006; 69: 425-427.
6. Fukumoto S, Yamashita T: FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone 2007; 40: 1190-1195.
7. Gutierrez O, et al: Fibroblast growth factor 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-22015.
8. Isakova T, et al: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
9. Isakova T, et al: Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19: 615-623.
10. El-Hajj Fuleihan G, et al: The parathyroid hormone circadian rhythm is truly endogenous-a general clinical research center study. J Clin Endocrinol Metab 1997; 82: 281-286.
11. Larsson T, et al: Circulating concentration of FGF23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279.
12. Gutierrez OM, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
13. Wolf M, et al: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
14. Isakova T, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
15. Fliser D, et al: Fibroblast growth factor 23 predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
16. Koiwa F, et al: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339.
17. Oliveira RB, et al: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
18. Vervloet MG, et al: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011; 6: 383-389.
19. Isakova T, et al: Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013 (E-pub ahead of print).
20. Isakova T, et al: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591.
21. Block GA, et al: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415.